APA

Al-Katib A. M., Aboukameel A., Ebrahim A., Beck F. W., Tekyi-Mensah S. E., Raufi A., Ahmed Y., Mandziara M. & Kafri Z. (20150504). Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. : Experimental hematology & oncology.

Chicago

Al-Katib Ayad M, Aboukameel Amro, Ebrahim AbdulShukkur, Beck Frances Wj, Tekyi-Mensah Samuel E, Raufi Ali, Ahmed Yasin, Mandziara Mary and Kafri Zyad. 20150504. Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. : Experimental hematology & oncology.

Harvard

Al-Katib A. M., Aboukameel A., Ebrahim A., Beck F. W., Tekyi-Mensah S. E., Raufi A., Ahmed Y., Mandziara M. and Kafri Z. (20150504). Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. : Experimental hematology & oncology.

MLA

Al-Katib Ayad M, Aboukameel Amro, Ebrahim AbdulShukkur, Beck Frances Wj, Tekyi-Mensah Samuel E, Raufi Ali, Ahmed Yasin, Mandziara Mary and Kafri Zyad. Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. : Experimental hematology & oncology. 20150504.